Abstract
Backkground: Management of asymptomatic early stage chronic lymphocytic leukemia (CLL) centered on expectant surveillance for active disease warranting chemotherapy. In CLL, elevated serum β-2 microglobulin (β2M) levels were associated with more rapid disease progression and shorter survival (OS). Methods: An early intervention trial was designed to assess response, time-to-progression (TTP), and OS after immunotherapy with standard-dose rituximab (375 mg/m2 intravenously weekly for 8 consecutive weeks) in 34 asymptomatic untreated early stage CLL with β2M level ≥ 2 mg/dL. Results: Long-term follow-up and results are reported. The overall response rate in 34 patients was 82% (9% complete [CR]), median TTP in the 28 responders was 23 months, the median time to subsequent treatment was 43 months, and the 8-year OS rate was 74% (median follow-up, 102 months). Conclusions: Early treatment with rituximab was well tolerated and safe. Further studies are needed to determine if this intervention can decrease CLL-related morbidity and mortality.
Original language | English (US) |
---|---|
Pages (from-to) | 3182-3186 |
Number of pages | 5 |
Journal | Cancer |
Volume | 117 |
Issue number | 14 |
DOIs | |
State | Published - Jul 15 2011 |
Externally published | Yes |
Keywords
- chronic lymphocytic leukemia
- early stage
- rituximab
- therapy
ASJC Scopus subject areas
- Oncology
- Cancer Research